Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

QTRX vs CDNA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
QTRX
Quanterix Corporation

Medical - Devices

HealthcareNASDAQ • US
Market Cap$129M
5Y Perf.-90.0%
CDNA
CareDx, Inc

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$1.11B
5Y Perf.-33.3%

QTRX vs CDNA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
QTRX logoQTRX
CDNA logoCDNA
IndustryMedical - DevicesMedical - Diagnostics & Research
Market Cap$129M$1.11B
Revenue (TTM)$145M$413M
Net Income (TTM)$-104M$-8M
Gross Margin44.1%48.2%
Operating Margin-96.4%-3.3%
Forward P/E22.8x
Total Debt$37M$20M
Cash & Equiv.$30M$65M

QTRX vs CDNALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

QTRX
CDNA
StockMay 20May 26Return
Quanterix Corporati… (QTRX)10010.0-90.0%
CareDx, Inc (CDNA)10066.7-33.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: QTRX vs CDNA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CDNA leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
QTRX
Quanterix Corporation
The Specific-Use Pick

In this particular matchup, QTRX is outpaced on most metrics by others in the set.

Best for: healthcare exposure
CDNA
CareDx, Inc
The Income Pick

CDNA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • beta 1.39
  • Rev growth 13.8%, EPS growth -143.0%, 3Y rev CAGR 5.7%
  • 385.1% 10Y total return vs QTRX's -84.3%
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthCDNA logoCDNA13.8% revenue growth vs QTRX's 2.6%
Quality / MarginsCDNA logoCDNA-2.0% margin vs QTRX's -71.9%
Stability / SafetyCDNA logoCDNABeta 1.39 vs QTRX's 1.98, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)CDNA logoCDNA+45.2% vs QTRX's -48.7%
Efficiency (ROA)CDNA logoCDNA-1.9% ROA vs QTRX's -26.0%, ROIC -5.7% vs -21.4%

QTRX vs CDNA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

QTRXQuanterix Corporation
FY 2025
Product
66.9%$93M
Service And Other Revenue
31.8%$44M
License and Service
1.1%$2M
Grant
0.2%$243,000
CDNACareDx, Inc
FY 2025
Service
85.0%$274M
Product
15.0%$48M

QTRX vs CDNA — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCDNALAGGINGQTRX

Income & Cash Flow (Last 12 Months)

CDNA leads this category, winning 6 of 6 comparable metrics.

CDNA is the larger business by revenue, generating $413M annually — 2.8x QTRX's $145M. CDNA is the more profitable business, keeping -2.0% of every revenue dollar as net income compared to QTRX's -71.9%. On growth, CDNA holds the edge at +39.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricQTRX logoQTRXQuanterix Corpora…CDNA logoCDNACareDx, Inc
RevenueTrailing 12 months$145M$413M
EBITDAEarnings before interest/tax-$125M$2M
Net IncomeAfter-tax profit-$104M-$8M
Free Cash FlowCash after capex-$83M$65M
Gross MarginGross profit ÷ Revenue+44.1%+48.2%
Operating MarginEBIT ÷ Revenue-96.4%-3.3%
Net MarginNet income ÷ Revenue-71.9%-2.0%
FCF MarginFCF ÷ Revenue-57.2%+15.8%
Rev. Growth (YoY)Latest quarter vs prior year+20.3%+39.0%
EPS Growth (YoY)Latest quarter vs prior year+30.2%+126.3%
CDNA leads this category, winning 6 of 6 comparable metrics.

Valuation Metrics

QTRX leads this category, winning 2 of 3 comparable metrics.
MetricQTRX logoQTRXQuanterix Corpora…CDNA logoCDNACareDx, Inc
Market CapShares × price$129M$1.1B
Enterprise ValueMkt cap + debt − cash$136M$1.1B
Trailing P/EPrice ÷ TTM EPS-1.10x-53.60x
Forward P/EPrice ÷ next-FY EPS est.22.85x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue0.93x2.92x
Price / BookPrice ÷ Book value/share0.40x3.77x
Price / FCFMarket cap ÷ FCF30.66x
QTRX leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

CDNA leads this category, winning 8 of 8 comparable metrics.

CDNA delivers a -2.6% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-35 for QTRX. CDNA carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to QTRX's 0.13x. On the Piotroski fundamental quality scale (0–9), CDNA scores 5/9 vs QTRX's 2/9, reflecting solid financial health.

MetricQTRX logoQTRXQuanterix Corpora…CDNA logoCDNACareDx, Inc
ROE (TTM)Return on equity-35.2%-2.6%
ROA (TTM)Return on assets-26.0%-1.9%
ROICReturn on invested capital-21.4%-5.7%
ROCEReturn on capital employed-24.7%-5.8%
Piotroski ScoreFundamental quality 0–925
Debt / EquityFinancial leverage0.13x0.06x
Net DebtTotal debt minus cash$7M-$46M
Cash & Equiv.Liquid assets$30M$65M
Total DebtShort + long-term debt$37M$20M
Interest CoverageEBIT ÷ Interest expense
CDNA leads this category, winning 8 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

CDNA leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in CDNA five years ago would be worth $2,759 today (with dividends reinvested), compared to $490 for QTRX. Over the past 12 months, CDNA leads with a +45.2% total return vs QTRX's -48.7%. The 3-year compound annual growth rate (CAGR) favors CDNA at 37.7% vs QTRX's -45.8% — a key indicator of consistent wealth creation.

MetricQTRX logoQTRXQuanterix Corpora…CDNA logoCDNACareDx, Inc
YTD ReturnYear-to-date-57.2%+12.0%
1-Year ReturnPast 12 months-48.7%+45.2%
3-Year ReturnCumulative with dividends-84.1%+161.1%
5-Year ReturnCumulative with dividends-95.1%-72.4%
10-Year ReturnCumulative with dividends-84.3%+385.1%
CAGR (3Y)Annualised 3-year return-45.8%+37.7%
CDNA leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

CDNA leads this category, winning 2 of 2 comparable metrics.

CDNA is the less volatile stock with a 1.39 beta — it tends to amplify market swings less than QTRX's 1.98 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CDNA currently trades 92.3% from its 52-week high vs QTRX's 31.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricQTRX logoQTRXQuanterix Corpora…CDNA logoCDNACareDx, Inc
Beta (5Y)Sensitivity to S&P 5001.98x1.39x
52-Week HighHighest price in past year$8.77$23.24
52-Week LowLowest price in past year$2.56$10.96
% of 52W HighCurrent price vs 52-week peak+31.4%+92.3%
RSI (14)Momentum oscillator 0–10042.356.4
Avg Volume (50D)Average daily shares traded937K667K
CDNA leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates QTRX as "Buy" and CDNA as "Buy". Consensus price targets imply 45.5% upside for QTRX (target: $4) vs 11.9% for CDNA (target: $24).

MetricQTRX logoQTRXQuanterix Corpora…CDNA logoCDNACareDx, Inc
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$4.00$24.00
# AnalystsCovering analysts1013
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+7.9%
Insufficient data to determine a leader in this category.
Key Takeaway

CDNA leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). QTRX leads in 1 (Valuation Metrics).

Best OverallCareDx, Inc (CDNA)Leads 4 of 6 categories
Loading custom metrics...

QTRX vs CDNA: Frequently Asked Questions

9 questions · data-driven answers · updated daily

01

Is QTRX or CDNA a better buy right now?

For growth investors, CareDx, Inc (CDNA) is the stronger pick with 13.

8% revenue growth year-over-year, versus 2. 6% for Quanterix Corporation (QTRX). Analysts rate Quanterix Corporation (QTRX) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — QTRX or CDNA?

Over the past 5 years, CareDx, Inc (CDNA) delivered a total return of -72.

4%, compared to -95. 1% for Quanterix Corporation (QTRX). Over 10 years, the gap is even starker: CDNA returned +385. 1% versus QTRX's -84. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — QTRX or CDNA?

By beta (market sensitivity over 5 years), CareDx, Inc (CDNA) is the lower-risk stock at 1.

39β versus Quanterix Corporation's 1. 98β — meaning QTRX is approximately 42% more volatile than CDNA relative to the S&P 500. On balance sheet safety, CareDx, Inc (CDNA) carries a lower debt/equity ratio of 6% versus 13% for Quanterix Corporation — giving it more financial flexibility in a downturn.

04

Which is growing faster — QTRX or CDNA?

By revenue growth (latest reported year), CareDx, Inc (CDNA) is pulling ahead at 13.

8% versus 2. 6% for Quanterix Corporation (QTRX). On earnings-per-share growth, the picture is similar: CareDx, Inc grew EPS -143. 0% year-over-year, compared to -151. 0% for Quanterix Corporation. Over a 3-year CAGR, QTRX leads at 9. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — QTRX or CDNA?

CareDx, Inc (CDNA) is the more profitable company, earning -5.

6% net margin versus -77. 1% for Quanterix Corporation — meaning it keeps -5. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CDNA leads at -5. 5% versus -62. 9% for QTRX. At the gross margin level — before operating expenses — CDNA leads at 67. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is QTRX or CDNA more undervalued right now?

Analyst consensus price targets imply the most upside for QTRX: 45.

5% to $4. 00.

07

Which pays a better dividend — QTRX or CDNA?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

08

Is QTRX or CDNA better for a retirement portfolio?

For long-horizon retirement investors, CareDx, Inc (CDNA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+385.

1% 10Y return). Quanterix Corporation (QTRX) carries a higher beta of 1. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CDNA: +385. 1%, QTRX: -84. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between QTRX and CDNA?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

QTRX

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Gross Margin > 26%
Run This Screen
Stocks Like

CDNA

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 19%
  • Gross Margin > 28%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform QTRX and CDNA on the metrics below

Revenue Growth>
%
(QTRX: 20.3% · CDNA: 39.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.